Preclinical evaluation of [13xLa]La-FAP-2286 as a novel theranostic agent for tumors expressing fibroblast activation protein

Abstract excerpt

In this study, a novel theranostic radiopharmaceutical, [ 13x La]La-FAP-2286, for targeting Fibroblast Activation Protein (FAP)-positive tumors. The theranostic pair of 132 La (half-life: 4.59 h, 42.1% β⁺) and 135 La (half-life: 18.91 h, 100% EC) was produced via proton bombardment of natural barium in a 30 MeV cyclotron, achieving high radionuclidic purity (99.9%) and radiochemical purity (RCP > 99%). Stability...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cardiac Structural Anomalies and Repair
• Share to Neuropeptides and Animal Physiology
• Share to Peptidase Inhibition and Analysis